Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside
about
Therapeutic potential of PDE modulation in treating heart diseaseRegulation of phosphodiesterase 3 and inducible cAMP early repressor in the heartManagement of the patient for transcatheter aortic valve implantation in the perioperative period.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Rationale for the short term use of intravenous milrinone under hemodynamic guidance in patients with severe systolic heart failure.Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.Intravenous milrinone in treatment of advanced congestive heart failureIntracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventriclePDE3 inhibition in dilated cardiomyopathy.Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients.Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions.Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery.Combined use of glucagon and milrinone may not be preferable for severe propranolol poisoning in the canine model.Milrinone versus glucagon: comparative hemodynamic effects in canine propranolol poisoning.Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass.Functions of PDE3 Isoforms in Cardiac Muscle.Comparison of the effects of amrinone, milrinone and olprinone in reversing bupivacaine-induced cardiovascular depression.Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation.Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone.Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.Dual Activation of Phosphodiesterases 3 and 4 Regulates Basal Spontaneous Beating Rate of Cardiac Pacemaker Cells: Role of Compartmentalization?
P2860
Q27005761-A55F0B4B-32B3-42AC-A857-BC3D02D9E786Q28291007-5DA13012-06AC-4144-A55D-816042E501FDQ30454993-2F99A284-2C26-48B3-B469-FB027A2FED1CQ33966155-DC9B9869-5426-4581-B173-63671004BEEEQ34074831-2A2A14A6-8A73-40BC-9318-97F01ED3369EQ34252901-EC643F24-A3E8-4B8B-8689-706F2844A124Q34766698-CBCF3616-740B-4935-A97F-E8B7B647ADF5Q35000998-049D3634-7C53-4C3C-B30F-8C8E5D7062E6Q35104244-53E5957E-0D6D-4CA5-B696-70470819018AQ35811171-755BC80C-7D50-461E-989B-8C08E48621E2Q35884425-162B122E-1CA7-4CE4-8F35-FE1250640E1CQ36512551-E1B43145-614D-46E2-B288-1F1133C1284FQ37362141-FA10083C-0DDF-484E-8C46-E8B73D440FEFQ37941174-C0AAAF10-3F5E-4458-91D5-03C913CA4191Q38334113-E2D3B7B0-A80E-454A-BF29-A8DA79C1A938Q38389477-BEC9ED6C-E49F-428C-B2C3-A290F773A535Q39790530-C7A98AB4-DC7E-4038-BF05-DEAE157988A5Q40852001-6AF48A52-405A-441D-A379-5D2F809AB8E1Q41768334-0A09DDDF-4E8E-4BBA-839A-C725937CB0BDQ42277287-F84BBB8A-DA05-4429-B9CF-692D34B3DA41Q42283155-CBBE6567-C7F3-4CE2-997C-3C57E192709FQ43573449-8D17C80E-86C4-4C75-9B94-EE13B130F4D2Q50132075-130BA9F4-49C6-4FE9-90A5-8C6F8BF219F3Q51375466-7B903B75-9030-4A3D-A76D-EA9D89E4D34EQ52006478-E43AFFA6-CD1F-4D53-B47A-23EC07F990FBQ54400640-CB2E4AF7-701A-4320-83DE-829F02DDD66FQ54976758-E8041EE4-3DA4-4394-8440-ED1CFA7F2A5FQ57817020-5AC0A6A7-530A-4B18-9D82-49C08D547465
P2860
Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside
description
1985 nî lūn-bûn
@nan
1985 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@ast
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@en
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@nl
type
label
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@ast
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@en
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@nl
prefLabel
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@ast
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@en
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@nl
P2093
P2860
P356
P1476
Positive inotropic and vasodil ...... nd comparison to nitroprusside
@en
P2093
E Braunwald
R F Wright
W S Colucci
P2860
P356
10.1172/JCI111742
P407
P577
1985-02-01T00:00:00Z